Last reviewed · How we verify

Pembrolizumab, Sintilimab

Hunan Province Tumor Hospital · Phase 3 active Small molecule

Pembrolizumab and Sintilimab are PD-1 inhibitors that block the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby releasing the brakes on anti-tumor immune responses.

Pembrolizumab and Sintilimab are PD-1 inhibitors that block the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby releasing the brakes on anti-tumor immune responses. Used for Non-small cell lung cancer, Melanoma, Head and neck squamous cell carcinoma.

At a glance

Generic namePembrolizumab, Sintilimab
Also known astime-of-day of administration of immunochemotherapy
SponsorHunan Province Tumor Hospital
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

These monoclonal antibodies bind to programmed death receptor-1 (PD-1) on the surface of T lymphocytes, preventing engagement with ligands PD-L1 and PD-L2 expressed by tumor cells and immune cells in the tumor microenvironment. By blocking this inhibitory checkpoint, the drugs restore T cell proliferation, activation, and cytotoxic function, enabling the immune system to recognize and eliminate cancer cells. This mechanism is particularly effective in tumors with high PD-L1 expression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: